Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318805 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 3
- Study locations
NCT07318805: Recruiting Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer, sponsored by Pfizer.
NCT07318805 is a Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 260 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318805, a Phase 1 study of Colorectal Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.
Primary Outcome
Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Fulvestrant
- DRUG PF-08032562
Study Locations (3)
Michigan
- START Midwest, LLC - Grand Rapids
Texas
- START San Antonio - San Antonio
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-04-14 |
| Phase | Phase 1 |
What NCT07318805 shows while recruiting
NCT07318805 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (83% lower).
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT07318805 reports a single indexed study location in Michigan, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT07318805 about?
NCT07318805 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors". The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu...
What is the current status of trial NCT07318805?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2025-12-16. Estimated completion is 2030-04-14.
What conditions does trial NCT07318805 study?
This clinical trial studies the following conditions: Colorectal Cancer, Triple Negative Breast Cancer, Advanced Breast Cancer, Metastatic Colorectal Adenocarcinoma, Metastatic Breast Cancer (HR+/ HER2-).
What interventions are being tested in trial NCT07318805?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG), Fulvestrant (DRUG), PF-08032562 (DRUG).
Who is sponsoring clinical trial NCT07318805?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07318805 being conducted?
This trial has 3 study locations across Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07318805's enrollment target sits among peer trials
260 125th of 381 higher than 256 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI